

TUBERCULOSIS

AND THE

TUBERCLE BACILLUS

2ND EDITION



EDITED BY

WILLIAM R. JACOBS, JR., HELEN MCSHANE, VALERIE MIZRAHI, AND IAN M. ORME

TUBERCULOSIS

— AND THE —

TUBERCLE BACILLUS

— 2ND EDITION —

TUBERCULOSIS

AND THE

TUBERCLE BACILLUS

2ND EDITION

EDITED BY

William R. Jacobs, Jr.

Department of Immunology
and Microbiology, Albert
Einstein School of Medicine,
Bronx, New York

Helen McShane

Cellular Immunology and
Vaccine Development Group,
Nuffield Department of
Medicine, Jenner Institute,
University of Oxford, Oxford,
United Kingdom

Valerie Mizrahi

Institute of Infectious
Disease and Molecular
Medicine, University of Cape
Town, Faculty of Health
Sciences, Rondebosch,
South Africa

Ian M. Orme

Department of Microbiology,
Immunology, and Pathology,
Colorado State University,
Fort Collins, Colorado



**ASM
PRESS**

AMERICAN SOCIETY FOR MICROBIOLOGY
WASHINGTON, DC

Cover images: Cording *M. tuberculosis* infected by fluorescent reporter phage ϕ^2 DRM9, courtesy of Paras Jain and Torin Weisbrod, Albert Einstein College of Medicine, Bronx, NY.

Copyright © 2018 by ASM Press. ASM Press is a registered trademark of the American Society for Microbiology. All rights reserved. No part of this publication may be reproduced or transmitted in whole or in part or reutilized in any form or by any means, electronic or mechanical, including photocopying and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Disclaimer: To the best of the publisher's knowledge, this publication provides information concerning the subject matter covered that is accurate as of the date of publication. The publisher is not providing legal, medical, or other professional services. Any reference herein to any specific commercial products, procedures, or services by trade name, trademark, manufacturer, or otherwise does not constitute or imply endorsement, recommendation, or favored status by the American Society for Microbiology (ASM). The views and opinions of the author(s) expressed in this publication do not necessarily state or reflect those of ASM, and they shall not be used to advertise or endorse any product.

Library of Congress Cataloging-in-Publication Data

Names: Jacobs, William R., Jr., editor.

Title: Tuberculosis and the tubercle bacillus / edited by William R. Jacobs, Jr., Department of Immunology and Microbiology, Albert Einstein School of Medicine, Bronx, New York, Helen McShane, Cellular Immunology and Vaccine Development Group, Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, United Kingdom, Valerie Mizrahi, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Faculty of Health Sciences, Rondebosch, South Africa, Ian M. Orme, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado.

Description: 2nd edition. | Washington, DC : ASM Press, [2018] | Includes bibliographical references and index.

Identifiers: LCCN 2017038089 (print) | LCCN 2017040375 (ebook) |

ISBN 9781555819569 (ebook) | ISBN 9781555819552 (print)

Subjects: LCSH: Tuberculosis.

Classification: LCC QR201.T6 (ebook) | LCC QR201.T6 T83 2018 (print) | DDC 614.5/42--dc23

LC record available at <https://lccn.loc.gov/2017038089>

doi:10.1128/9781555819569

Printed in Canada

10 9 8 7 6 5 4 3 2 1

Address editorial correspondence to: ASM Press, 1752 N St., N.W., Washington, DC 20036-2904, USA.

Send orders to: ASM Press, P.O. Box 605, Herndon, VA 20172, USA.

Phone: 800-546-2416; 703-661-1593. Fax: 703-661-1501.

E-mail: books@asmusa.org

Online: <http://www.asmscience.org>

Contents

Contributors ix

Preface xiii

SECTION I

TOWARDS EDWARD JENNER'S REVENGE: DEVELOPING AN EFFECTIVE TUBERCULOSIS VACCINE / 1

A. BASIC IMMUNOLOGY

- 1 **Innate Immune Responses to Tuberculosis / 3**
JEFFREY S. SCHOREY AND LARRY S. SCHLESINGER
- 2 **Cytokines and Chemokines in *Mycobacterium tuberculosis* Infection / 33**
RACQUEL DOMINGO-GONZALEZ, OLIVER PRINCE,
ANDREA COOPER, AND SHABAANA KHADER
- 3 **Regulation of Immunity to Tuberculosis / 73**
SUSANNA BRIGHENTI AND DIANE J. ORDWAY
- 4 **The Memory Immune Response to Tuberculosis / 95**
JOANNA R. KIRMAN, MARCELA I. HENAO-TAMAYO,
AND ELSE MARIE AGGER
- 5 **Pathology of Tuberculosis: How the Pathology of Human Tuberculosis Informs and Directs Animal Models / 117**
RANDALL J. BASARABA AND ROBERT L. HUNTER

B. ANIMAL MODELS

- 6 **Animal Models of Tuberculosis: An Overview / 131**
ANN WILLIAMS AND IAN M. ORME
- 7 **Mouse and Guinea Pig Models of Tuberculosis / 143**
IAN M. ORME AND DIANE J. ORDWAY
- 8 **Non-Human Primate Models of Tuberculosis / 163**
JULIET C. PEÑA AND WEN-ZHE HO
- 9 **Experimental Infection Models of Tuberculosis in Domestic Livestock / 177**
BRYCE M. BUDDLE, H. MARTIN VORDERMEIER,
AND R. GLYN HEWINSON

C. VACCINES

- 10 **Clinical Testing of Tuberculosis Vaccine Candidates / 193**
MARK HATHERILL, DERECK TAIT,
AND HELEN MCSHANE

D. HUMAN IMMUNOLOGY

- 11 **Human Immunology of Tuberculosis / 213**
THOMAS J. SCRIBA, ANNA K. COUSSENS,
AND HELEN A. FLETCHER

- 12 The Immune Interaction between HIV-1 Infection and *Mycobacterium tuberculosis* / 239
ELSA DU BRUYN AND ROBERT JOHN WILKINSON

SECTION II

DRUG DISCOVERY AND DEVELOPMENT: STATE OF THE ART AND FUTURE DIRECTIONS / 269

- 13 Preclinical Efficacy Testing of New Drug Candidates / 271
ERIC L. NUERMBERGER
- 14 Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions / 295
GREGORY M. COOK, KIEL HARDS, ELYSE DUNN, ADAM HEIKAL, YOSHIO NAKATANI, CHRIS GREENING, DEAN C. CRICK, FABIO L. FONTES, KEVIN PETHE, ERIK HASENOEHL, AND MICHAEL BERNEY
- 15 Targeting Phenotypically Tolerant *Mycobacterium tuberculosis* / 317
BEN GOLD AND CARL NATHAN

SECTION III

BIOMARKERS AND DIAGNOSTICS / 361

- 16 Tuberculosis Diagnostics: State of the Art and Future Directions / 363
MADHUKAR PAI, MARK P. NICOL, AND CATHARINA C. BOEHME
- 17 Latent *Mycobacterium tuberculosis* Infection and Interferon-Gamma Release Assays / 379
MADHUKAR PAI AND MARCEL BEHR
- 18 Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control / 389
WENDY SUSAN STEVENS, LESLEY SCOTT, LARA NOBLE, NATASHA GOUS, AND KEERTAN DHEDA

SECTION IV

HOST AND STRAIN DIVERSITY / 411

- 19 The Role of Host Genetics (and Genomics) in Tuberculosis / 413
VIVEK NARANBHAI

- 20 The Evolutionary History, Demography, and Spread of the *Mycobacterium tuberculosis* Complex / 453
MAXIME BARBIER AND THIERRY WIRTH

- 21 Impact of Genetic Diversity on the Biology of *Mycobacterium tuberculosis* Complex Strains / 475
STEFAN NIEMANN, MATTHIAS MERKER, THOMAS KOHL, AND PHILIP SUPPLY

- 22 Evolution of *Mycobacterium tuberculosis*: New Insights into Pathogenicity and Drug Resistance / 495
EVA C. BORITSCH AND ROLAND BROSCH

SECTION V

THE SIGNATURE PROBLEM OF TUBERCULOSIS PERSISTENCE / 517

- 23 Acid-Fast Positive and Acid-Fast Negative *Mycobacterium tuberculosis*: The Koch Paradox / 519
CATHERINE VILCHÈZE AND LAURENT KREMER
- 24 Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions / 533
RANDALL J. BASARABA AND ANIL K. OJHA
- 25 Killing *Mycobacterium tuberculosis* *In Vitro*: What Model Systems Can Teach Us / 541
TRACY L. KEISER AND GEORGIANA E. PURDY
- 26 Epigenetic Phosphorylation Control of *Mycobacterium tuberculosis* Infection and Persistence / 557
MELISSA RICHARD-GREENBLATT AND YOSSEF AV-GAY
- 27 DNA Replication in *Mycobacterium tuberculosis* / 581
ZANELE DITSE, MEINDERT H. LAMERS, AND DIGBY F. WARNER
- 28 The Sec Pathways and Exportomes of *Mycobacterium tuberculosis* / 607
BRITTANY K. MILLER, KATELYN E. ZULAUF, AND MIRIAM BRAUNSTEIN
- 29 The Role of ESX-1 in *Mycobacterium tuberculosis* Pathogenesis / 627
KA-WING WONG

- 30 **The Minimal Unit of Infection:
Mycobacterium tuberculosis in the
Macrophage / 635**
BRIAN C. VANDERVEN, LU HUANG,
KYLE H. ROHDE, AND DAVID G. RUSSELL
- 31 **Metabolic Perspectives on Persistence / 653**
TRAVIS E. HARTMAN, ZHE WANG,
ROBERT S. JANSEN, SUSANA GARDETE,
AND KYU Y. RHEE
- 32 **Phenotypic Heterogeneity in *Mycobacterium
tuberculosis* / 671**
NEERAJ DHAR, JOHN MCKINNEY, AND
GIULIA MANINA
- 33 ***Mycobacterium tuberculosis* in the Face of
Host-Imposed Nutrient Limitation / 699**
MICHAEL BERNEY AND LINDA BERNEY-MEYER
- Index / 717**

Contributors

Else Marie Agger

Department of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark

Yossef Av-Gay

Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, Canada

Maxime Barbier

Laboratoire Biologie Intégrative des Populations, Evolution Moléculaire; Institut de Systématique, Evolution, Biodiversité, UMR-CNRS 7205, Muséum National d'Histoire Naturelle, Univ. Pierre et Marie Curie, EPHE, Sorbonne Universités, Paris, France

Randall J. Basaraba

Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado

Marcel Behr

McGill International TB Centre & Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada

Michael Berney

Albert Einstein College of Medicine, Department of Microbiology and Immunology, New York, New York

Linda Berney-Meyer

Albert Einstein College of Medicine, Department of Microbiology and Immunology, New York, New York

Catharina C. Boehme

FIND, Geneva, Switzerland

Eva C. Boritsch

Institut Pasteur, Unit for Integrated Mycobacterial Pathogenomics, Paris, France

Miriam Braunstein

Department of Microbiology and Immunology, University of North Carolina – Chapel Hill, Chapel Hill, North Carolina

Susanna Brighenti

Center for Infectious Medicine (CIM), F59, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

Roland Brosch

Institut Pasteur, Unit for Integrated Mycobacterial Pathogenomics, Paris, France

Bryce M. Buddle

AgResearch, Hopkirk Research Institute, Palmerston North, New Zealand

Gregory M. Cook

University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand, and Maurice Wilkins Center for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand

Andrea Cooper

University of Leicester, Infection Immunity and Inflammation, Leicester, Leicestershire, United Kingdom

Anna K. Coussens

Clinical Infectious Diseases Research Initiative, Division of Medical Microbiology, Department of Pathology, and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Dean C. Crick

Colorado State University, Department of Microbiology, Immunology, and Pathology, Fort Collins, Colorado

Neeraj Dhar

Global Health Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

Keertan Dheda

Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa

Zanele Ditse

MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DST/NRF Centre of Excellence for Biomedical TB Research, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

Racquel Domingo-Gonzalez

Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, Missouri

Elsa du Bruyn

Clinical Infectious Diseases Research Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory, Republic of South Africa

Elyse Dunn

University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand

Helen A. Fletcher

Immunology and Infection Department, London School of Hygiene & Tropical Medicine, London, United Kingdom

Fabio L. Fontes

Colorado State University, Department of Microbiology, Immunology, and Pathology, Fort Collins, Colorado

Susana Gardete

Department of Medicine, Division of Infectious Diseases, Weill Cornell Medical College, New York, New York

Ben Gold

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York

Natasha Gous

Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service and National Priority Program of the National Health Laboratory Service, Johannesburg, South Africa

Chris Greening

The Commonwealth Scientific and Industrial Research Organization, Land and Water Flagship, Acton, Australia, and Monash University, School of Biological Sciences, Clayton, Victoria, Australia

Kiel Hards

University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand

Travis E. Hartman

Department of Medicine, Division of Infectious Diseases, Weill Cornell Medical College, New York, New York

Erik Hasenoehrle

Albert Einstein College of Medicine, Department of Microbiology and Immunology, Bronx, New York

Mark Hatherill

South African Tuberculosis Vaccine Initiative (SATVI) and Institute of Infectious Disease & Molecular Medicine

(IDM), University of Cape Town, Wernher & Beit South Building, Anzio Road, Observatory, Cape Town, South Africa

Adam Heikal

University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand, and Maurice Wilkins Center for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand

Marcela I. Henao-Tamayo

Department of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratory, Colorado State University, Fort Collins, Colorado

R. Glyn Hewinson

Animal and Plant Health Agency – Weybridge, Addlestone, Surrey, United Kingdom

Wen-Zhe Ho

Animal Biosafety Level III Laboratory, Center for Animal Experiment, State Key Laboratory of Virology, Wuhan University, Wuhan, China; Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania

Lu Huang

Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York

Robert L. Hunter

Department of Pathology and Laboratory Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas

Robert S. Jansen

Department of Medicine, Division of Infectious Diseases, Weill Cornell Medical College, New York, New York

Tracy L. Keiser

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York

Shabaana Khader

Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, Missouri

Joanna R. Kirman

Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand

Thomas Kohl

Molecular Mycobacteriology, Forschungszentrum Borstel, Leibniz-Zentrum für Medizin und Biowissenschaften, Borstel, Germany

Laurent Kremer

IRIM (ex-CPBS) UMR 9004, Infectious Disease Research Institute of Montpellier (IDRIM), Université de Montpellier, CNRS, Montpellier, France

Giulia Manina

Microbial Individuality and Infection Group, Institut Pasteur, 25 rue du Docteur Roux, Paris, France

John McKinney

Global Health Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

Helen McShane

The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, United Kingdom

Matthias Merker

Molecular Mycobacteriology, Forschungszentrum Borstel, Leibniz-Zentrum für Medizin und Biowissenschaften, Borstel, Germany

Brittany K. Miller

Department of Microbiology and Immunology, University of North Carolina – Chapel Hill, Chapel Hill, North Carolina

Yoshio Nakatani

University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand, and Maurice Wilkins Center for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand

Vivek Naranbhai

Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, and Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa

Carl Nathan

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York

Mark P. Nicol

University of Cape Town, Cape Town, South Africa

Stefan Niemann

Molecular Mycobacteriology, Forschungszentrum Borstel, Leibniz-Zentrum für Medizin und Biowissenschaften, and German Center for Infection Research (DZIF), partner site Borstel, Borstel, Germany

Lara Noble

Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

Eric L. Nuermberger

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, and Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Anil K. Ojha

Wadsworth Center, NY State Department of Health and University at Albany, Albany, New York

Diane J. Ordway

Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado

Ian M. Orme

Colorado State University, Fort Collins, Colorado

Madhukar Pai

McGill International TB Centre & Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada

Juliet C. Peña

Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, 3500 N. Broad St., MERB 843, Philadelphia, Pennsylvania

Kevin Pethe

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

Oliver Prince

Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, Missouri

Georgiana E. Purdy

Department of Microbiology and Immunology, Oregon Health Sciences University, Portland, Oregon

Kyu Y. Rhee

Department of Medicine and Department of Microbiology & Immunology, Division of Infectious Diseases, Weill Cornell Medical College, New York, New York

Melissa Richard-Greenblatt

Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, Canada

Kyle H. Rohde

Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida

David G. Russell

Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York

Larry S. Schlesinger

Department of Microbial Infection and Immunity, Center for Microbial Interface Biology, The Ohio State University, Columbus, Ohio

Jeffrey S. Schorey

Department of Biological Sciences, Eck Institute for Global Health, Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, Indiana

Lesley Scott

Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

Thomas J. Scriba

South African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Wendy Susan Stevens

Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service, and National Priority Program of the National Health Laboratory Service, Johannesburg, South Africa

Philip Supply

INSERM U1019; CNRS UMR 8204; Institut Pasteur de Lille, Center for Infection and Immunity of Lille; and Université Lille Nord de France, Lille, France

Dereck Tait

Aeras, Blackriver Park, First Floor, Observatory, Cape Town, South Africa

Brian C. VanderVen

Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York

Catherine Vilchèze

Howard Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York

H. Martin Vordermeier

Animal and Plant Health Agency – Weybridge, Addlestone, Surrey, United Kingdom

Zhe Wang

Department of Medicine, Division of Infectious Diseases, Weill Cornell Medical College, New York, New York

Digby F. Warner

MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Rondebosch, South Africa

Robert John Wilkinson

Department of Medicine, Imperial College London, and The Francis Crick Institute Mill Hill Laboratory, London, United Kingdom

Ann Williams

Health UK, Porton Down, Salisbury, United Kingdom

Thierry Wirth

Laboratoire Biologie Intégrative des Populations, Evolution Moléculaire; Institut de Systématique, Evolution, Biodiversité, UMR-CNRS 7205, Muséum National d'Histoire Naturelle, Univ. Pierre et Marie Curie, EPHE, Sorbonne Universités, Paris, France

Ka-Wing Wong

Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, People's Republic of China

Katelyn E. Zulauf

Department of Microbiology and Immunology, University of North Carolina – Chapel Hill, Chapel Hill, North Carolina

Preface: Combating Tuberculosis: Edward Jenner's Revenge

It is the height of irony that the man who discovered the smallpox vaccine, Edward Jenner, lost both his wife and son to tuberculosis (TB). By the time smallpox was essentially eradicated, it is estimated that over 300 million people had died from this disease over the preceding century. Its eventual prevention—by a simple vaccine—clearly illustrates the power of scientific discovery and how its application can affect human health. Hundreds of millions of people have been spared death and suffering from infectious diseases because of the development of vaccines and chemotherapeutic agents in the last 100 years. Millions of lives have been saved with the use of the TB vaccine, BCG, and the development of chemotherapeutic regimens for TB. Depressingly, despite these effective interventions, TB remains one of the most challenging problems of global health, with over 9 million new cases and 1.6 million deaths each year. This crisis has been further compounded by the emergence of the HIV epidemic, as this explosive and deadly combination has dramatically increased the global spread of TB, including increasing numbers of cases of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB.

Historically, mycobacterial disease has long been at the forefront of scientific discovery for infectious diseases. The leprosy bacillus, *Mycobacterium leprae*, the first bacterium to be associated with human disease, was initially visualized by Gerhard Armauer Hansen in 1873. Earlier, Jean Antoine Villemin was the first person to realize that lung tubercles were infectious and not cancerous. By the 1880s, Robert Koch, aware of both of these discoveries, not only observed the tubercle bacilli in tubercles, but developed a growth medium of heated serum to cultivate the tubercle bacillus out-

side of humans. He went on to repeat the transfer experiment of Villemin and transferred the disease of TB to numerous animal species, establishing the experimental paradigm (“the postulates”) of how to prove that an infectious agent is a cause of a disease. Koch’s findings led Albert Calmette and Camille Guérin to follow Jenner’s approach of developing an attenuated pathogen for use as a vaccine, using the bovine tubercle bacillus to develop the bacille Calmette-Guérin (BCG) vaccine that bears their names and is still used to this day.

It is noteworthy that Paul Ehrlich was sitting in the lecture hall when Robert Koch presented his work in 1882; he later went on to help Koch improve his staining techniques. By observing the selective staining of various cell types, including human cells and different bacteria, Ehrlich also developed the idea of chemotherapy—“magic bullets” that could kill microbial pathogens. He tried for years to develop a chemical that could kill the tubercle bacillus, with little success, though at the same time was far more successful in developing a treatment for syphilis. In the 1930s, his protégé Gerhard Domagk discovered the first sulfonamide to treat bacterial infections such as streptococcus, and as this fledgling field expanded, para-amino salicylic acid and isoniazid were discovered to be active against the TB bacillus. Parallel studies by Salman Waksman and Albert Schatz in the 1950s led to the discovery of streptomycin, the first bactericidal drug for the tubercle bacilli.

Despite these many historical advances, the TB bacillus—*Mycobacterium tuberculosis*—has proven to be a formidable adversary against numerous interventions. Nevertheless, despite the arduous challenges of

working with this dangerous pathogen, the field continues to persevere, and our continued success in the pursuit of knowledge would, we suspect, be applauded by Koch, Ehrlich, Calmette, and many others, as we strive to find and apply more effective cures for this dreadful disease. In this spirit, this textbook is a collection of state-of-the-art research aimed at understanding the TB bacillus, the way it infects its host, the mechanisms by which it persists in the face of host immunity, and current intervention and therapeutic methods. The contributors of this book believe that such continued

and dedicated research efforts will eventually lead to better vaccines, better chemotherapies, and ultimately the eradication of TB—Edward Jenner’s revenge.

WILLIAM R. JACOBS, JR.

HELEN MCSHANE

VALERIE MIZRAHI

IAN M. ORME

Towards Edward Jenner's Revenge: Developing an Effective Tuberculosis Vaccine

I

- A. BASIC IMMUNOLOGY
- B. ANIMAL MODELS
- C. VACCINES
- D. HUMAN IMMUNOLOGY

A. BASIC IMMUNOLOGY

Innate Immune Responses to Tuberculosis

1

Jeffrey S. Schorey¹ and Larry S. Schlesinger²

INTRODUCTION

Tuberculosis (TB) remains one of the leading causes of death by an infectious agent, accounting for approximately 1.3 million deaths per year (1). Despite its clinical significance, there are still significant gaps in our understanding of *Mycobacterium tuberculosis* pathogenesis and the host mechanisms that limit active disease to approximately 10% of those infected. Nevertheless, we continue to gain insight into the dynamic interplay between pathogen and host, with much of the focus centered on the lung microenvironment because this is the initial and primary site of infection. The lung as the initial “battlefield” provides unique challenges to both the host and pathogen because the host must balance the inflammatory response to limit the damage to lung tissue while inducing a sufficient immune response to control the infection. In contrast, the *M. tuberculosis* organism must avoid or circumvent the initial defensive barriers present within the respiratory tract to gain access to its host cell, the alveolar macrophage (AM). The AM response to infection as well as the reaction of other lung immune and nonimmune cells and non-cellular components is critical to determining whether the host will directly eliminate the pathogen or will in concert with the acquired immune system develop a protective granulomatous response. In addition, since bacteria disseminate during the early events in infection, engagement of innate immune components outside of the lung is also critical in shaping the host response. These early host processes which constitute the innate immune system will be the focus of this article.

LUNG

The lung is responsible for mediating gas exchange across a respiratory surface of 130 m², which is more than 60 times the surface of the body (2–4) (Fig. 1). On average, this involves inhalation of 14,000 liters of air each day (5) and processing not only of CO₂ and O₂, but also of pollutants, allergens, and microbes from the inhaled air. Efficient gas exchange requires a thin barrier between the air and blood; in some instances this barrier is composed of only one endothelial cell and one epithelial cell and is less than 2 μm thick. The lung must maintain this thin barrier while clearing inhaled insults (2–4).

The lung uses multiple defenses to clear contaminants from the air (discussed in more detail below). Briefly, basic instincts such as the coughing and sneezing reflex remove particulates from the lung. Mucus, together with cilia, forms the mucociliary escalator which transfers particles up the trachea for removal. Also, epithelial cells in the airway secrete antimicrobials including lysozyme and antimicrobial peptides such as defensins and cathelicidins (6, 7). These defenses clear particulates ≥5 μm. Anything smaller passes through the conducting system with velocity, eventually settling in the alveoli, where alveolar cells become responsible for their clearance.

The main three cell types in the alveolus are type I and type II alveolar epithelial cells (AECs) and AMs. These cells are coated by alveolar fluid and surfactant. External to the alveolus is the alveolar septum, which contains blood vessels, fibroblasts, protein fibers, and

¹Department of Biological Sciences, Eck Institute for Global Health, Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, IN 46556; ²Department of Microbial Infection and Immunity, Center for Microbial Interface Biology, The Ohio State University, Columbus, OH 43210.




Figure 1 Schematic of the lung and the role of pulmonary innate immune cells during *M. tuberculosis* infection. From left to right: branching of the airways, culminating in the alveolar sacs and the alveolus. Also depicted are the cells in the alveolus. Abbreviations: AEC I and II, type I and II alveolar epithelial cell; AM, alveolar macrophage; DC, dendritic cell; IM, interstitial macrophage; IVM, intravascular macrophage.

pores of Kohn. The fibers are responsible for the structural integrity of the alveolus. The pores of Kohn are holes in the septum that connect alveoli to each other, are filled with surfactant, and provide a passage for cells to migrate between alveoli (2, 8).

Lung Cellular Components

AECs

Although type I AECs constitute only 8% of peripheral lung cells (a third of the cells in the alveolus), they cover ~95% of the alveolar surface. Their thin flat shape, as well as their contact with endothelial cells of the pulmonary capillaries, provides the necessary thin surface for gas exchange to occur (2, 3). The cuboidal type II AECs constitute about 15% of peripheral lung cells, cover 5% of the alveolar surface, and have a smaller surface area than type I AECs—250 μm^2 compared to 5,000 μm^2 (9, 10). Type II AECs contain distinctive lamellar bodies and have apical microvilli. These cells secrete surfactant phospholipids and proteins, as well as lysozyme and antimicrobial peptides in lamellar bodies (7, 9). Following lung damage, type II AECs can serve as precursors to type I cells and self-renew (2, 3, 7). These cells also express HLA class I and II molecules (9), and murine cells can present mycobacterial antigens (11).

Lung macrophages

AMs constitute the majority of cells collected from bronchoalveolar lavage ($\geq 90\%$). They maintain the alveolar microenvironment, removing debris, dead cells, and microbes. They are long lived, with a half-life of 1 to 8 months (12, 13); about 40% of total AMs turn over each year (14). AMs are thought to originate from peripheral blood monocytes following migration into the lung (15) but may also originate from lung macrophages in response to inflammation (12, 16–20).

AMs must exert tightly regulated pro- and anti-inflammatory actions to control infection without damaging the fragile alveolar environment (14, 21). Thus, they exhibit characteristics of M1 (classically activated) and M2 (alternatively activated) macrophages (22). They express high levels of mannose receptor (MR), scavenger receptor-A, Toll-like receptor 9 (TLR9), and the nuclear receptor peroxisome proliferator-associated receptor gamma (PPAR γ), and low levels of TLR2 and the costimulatory molecules CD80 and CD86 (14, 21, 23). PPAR γ expression may be important for differentiation of AMs (24), which are highly phagocytic (25) but have a limited oxidative burst relative to neutrophils or peripheral blood mononuclear cells (PBMCs) (25, 26) and are weakly bactericidal (12). AMs are poor antigen presenters (27) and downregulate the abil-

ity of dendritic cells (DCs) to present antigen (28) and suppress lymphocyte activation (29).

The lung contains three types of macrophages, named based on their location: AMs, intravascular macrophages (IVMs), and interstitial macrophages (IMs). IVMs are located in the capillaries on endothelial cells, and IMs are in the interstitial space between alveoli (30, 31). The IVMs and IMs are less well understood than AMs, likely due to the difficulty isolating them. AMs are readily isolated from bronchoalveolar lavage following only a few washes, while IMs are obtained from the bronchoalveolar lavage following many washes (31), and many animals such as mice and humans (in contrast to pigs and horses, for example) may not constitutively produce IVMs (30). In rhesus macaques IMs were shown to have a higher turnover rate and be shorter lived than AMs (32). IMs are thought to regulate tissue fibrosis, inflammation, and antigen presentation (33) and be more proinflammatory than AMs (32). IVMs are phagocytic and may clear erythrocytes and fibrin from the blood (30).

DCs

A few DCs are located in the alveoli interstitial space, but most are in the conducting airways (2, 34). In the alveoli, they sit below the AECs and extend membrane protrusions to sample the inner surface of the airway lumen (35). Following antigen processing and presentation, DCs migrate to local lymph nodes (36) and inducible bronchus-associated lymphoid tissue that forms in response to infection or inflammation (37, 38). There are few lymphatic vessels around the alveoli, so alveolar DCs must migrate through the interstitium to access sites of lymphatic drainage (2). Other immune cells, including T and B cells, are found in low amounts in the interstitium.

Mucosal associated invariant T (MAIT) cells

Major histocompatibility complex (MHC)-related protein 1-restricted MAIT cells are unconventional CD8 T cells (39) and are present in the lung airways. MAIT cells detect antigen-presenting cells infected with fungi and bacteria, including *M. tuberculosis*. Following stimulation, MAIT cells produce gamma interferon (IFN- γ) and tumor necrosis factor (TNF) and lyse infected cells (40–42). They are important *in vivo* during mycobacterial infection. MHC-related protein 1 knockout mice show elevated bacillus Calmette-Guérin (BCG) growth compared to wild-type mice (43). Individuals with active TB have reduced levels of MAIT cells in the peripheral blood and enhanced levels in the lung compared with healthy individuals (40).

Neutrophils

Although under conditions of health lung alveoli contain predominantly macrophages, rapid recruitment of neutrophils is well known to be a key determinant of the innate immune response to bacterial pathogens (44). Neutrophils possess potent extracellular and intracellular killing mechanisms. However, severe bacterial lung infections are caused by excessive neutrophil-mediated inflammation. Neutrophils sense bacteria and/or their components and migrate across epithelia along a chemotactic gradient. Neutrophil sequestration is an essential antibacterial defense mechanism in the lung, which involves multiple steps, including activation of transcription factors, production of chemokines, upregulation of cell adhesion molecules, and enhancement of cell-cell interactions.

Mucus and Surfactant

Mucins are the main glycoproteins in mucus and are either tethered to epithelial cells or secreted. They are produced by submucosal glands and goblet cells, club cells, and alveolar cells in the conducting and peripheral airways. They bind particles and microbes to prevent their adherence to host cells and thus mediate clearance via the mucociliary escalator (7).

Pulmonary surfactant is produced by type II AECs in the alveoli and is a complex mixture of lipids and proteins that bathe cells in the alveolus and reduce surface tension to prevent alveolar collapse during expiration. Dipalmitoyl phosphatidylcholine is the most abundant phospholipid in surfactant (45), but surfactant also contains surfactant proteins (SPs) SP-A, SP-B, SP-C, and SP-D (46, 47). In general, SP-B and SP-C maintain stability of the surfactant lipids, while SP-A and SP-D are immunomodulators (7, 48). SP-A enhances apoptotic cell clearance by macrophages and regulates MR activity, the oxidative burst, and negative regulators of inflammation (49–54); SP-A also enhances macrophage phagocytosis of *M. tuberculosis* (55–58). In contrast, SP-D agglutinates *M. tuberculosis*, which decreases macrophage phagocytosis. However, the bacteria that are still phagocytosed show enhanced phagosome lysosome (PL) fusion and killing (59–61).

Soluble Components in the Surfactant Hypophase

Below the surfactant lipid monolayer is an aqueous hypophase of alveolar lining fluid (ALF) that contains substances with intrinsic antimicrobial properties which contribute to the innate immune response to pathogens within this environment (62). These include complement, antibody, defensins, lysozyme, phospholipases,

protease inhibitors, and homeostatic hydrolases that can affect the *M. tuberculosis* cell wall and host responses (63). ALF is generated, secreted, and recycled by AECs and is essential for maintaining lung function (64). Components of the complement system are produced by AECs (65) and macrophages in the lung (66). The complement system is active in the alveolar space and plays an important role in the microbe-macrophage encounter (67–71). TB is increased in the elderly, and recent studies show how the pulmonary environment, particularly ALF, in old age can potentially modify mucosal immune responses, including those in response to *M. tuberculosis* (72).

M. TUBERCULOSIS INTERACTION WITH THE LUNG

Initial Interactions Following Inhalation

Human ALF contains hydrolases that alter the *M. tuberculosis* cell wall, reducing exposure of mannose-capped lipoarabinomannan (ManLAM) and trehalose 6,6'-dimycolate (TDM; cord factor). ALF treatment of *M. tuberculosis* reduced its association with and intracellular replication in human macrophages and led to increased TNF- α release by macrophages (73). Thus, initial exposure to surfactant may alter the *M. tuberculosis* cell wall before interaction with AMs or AECs and affect subsequent interactions with the host, perhaps by altering the receptor primarily engaged by the bacteria.

Interactions with the Macrophage

Phagocytic receptors

The MR (CD206; MRC1) is highly expressed by AMs and subsets of DCs but not by monocytes (74–78) (Fig. 2). It is the dominant C-type lectin on human AMs and monocyte-derived macrophages, and it recognizes endogenous N-linked glycoproteins (79, 80) and mannose-containing pathogen-associated molecular patterns (PAMPs) (81) via its carbohydrate recognition domains. The MR discriminates between mannose-containing PAMPs based on the degree and nature of mannan motifs. It binds to the mannose caps of ManLAM (82, 83) and the higher-order phosphatidylinositol mannosides (PIMs) that are more mannosylated and found in greater amounts on pathogenic mycobacteria (84), thus differentiating among *M. tuberculosis* strains (85, 86). *M. tuberculosis* is thought to use molecular mimicry to bind the MR and mediate favorable entry into macrophages, and usage of the MR may be a marker of host adaptation (83). Binding

to the MR mediates phagocytosis of *M. tuberculosis* and leads to decreased PL fusion (84, 87, 88), acidification (89, 90), and oxidative burst (91), as well as release of anti-inflammatory cytokines (92). MR engagement also leads to increased PPAR γ activity, which allows for enhanced survival of *M. tuberculosis* in the macrophage, which is discussed in more detail below (23). The MR can facilitate presentation of lipids and ManLAM and serves as a prototypic pattern recognition receptor (PRR) linking innate and adaptive immunity, which has been exploited to deliver DNA vaccines to antigen-presenting cells (22) and is being used to modulate the immune system for therapeutic and vaccine purposes (93). The MR may also contribute to chronic stages of *M. tuberculosis* infection by mediating homotypic cellular adhesion and giant cell formation (94), which are characteristic of TB granulomas (95, 96).

DC-specific intercellular adhesion molecule 3 grabbing nonintegrin (DC-SIGN) is expressed by DCs and subsets of macrophages (77, 97) (Fig. 2). Its expression by human macrophages is generally low but can be induced following *M. tuberculosis* infection (98) or other stimulation (99). DC-SIGN recognizes mannosylated glycoconjugates such as *M. tuberculosis* ManLAM and PIMs (84, 100, 101). DC-SIGN activation during *M. tuberculosis* infection leads to PL fusion (contrary to the MR) and impedes DC maturation (100, 102).

Macrophage-inducible C-type lectin (Mincle; Clec4e, Clec5f9) is expressed on leukocytes at low levels before activation but is highly expressed on mouse macrophages following stimulation (103) (Fig. 2). Mincle recognizes damaged cells and fungi (104, 105). It also recognizes *M. tuberculosis* TDM, resulting in enhanced inflammatory cytokine production and granuloma formation (106, 107), but is not required for control of *M. tuberculosis* infection in mice (108).

Dectin-1 is a nonclassical C-type lectin that recognizes β -glucans (109) (Fig. 2). It is highly expressed on DCs, macrophages, monocytes, neutrophils, and a subset of T cells (110). Dectin-1 activation in conjunction with TLR4 during *M. tuberculosis* infection induces an interleukin (IL)-17A response (111). Similar to the MR, Dectin-1 differentiates between mycobacterium strains; activation by nonpathogenic (*Mycobacterium smegmatis*, *Mycobacterium phlei*) and attenuated (*Mycobacterium bovis* BCG, *M. tuberculosis* H₃₇R_a) mycobacteria, but not virulent *M. tuberculosis* H₃₇R_v, enhances TNF- α , IL-6, and RANTES production by macrophages (112, 113). Dectin-1 activation inhibits replication of BCG, but not virulent *M. tuberculosis*, in human macrophages (114). Dectin-2 recognizes mannose-




Figure 2 Macrophage receptors known to engage *M. tuberculosis* (*M.tb*) or its components and the downstream effects of receptor engagement on cytokine production, phagosome-lysosome fusion, and inflammation. Engagement of different receptors results in a macrophage response that can either promote or limit host immunity to *M. tuberculosis* infection.

containing lipids and is expressed by DC subsets and macrophages (115). Its stimulation by ManLAM induces pro- and anti-inflammatory responses and promotes T cell-mediated adaptive immunity in mice (116). Dectin-3 (also called MCL and Clec4d) recognizes TDM and is required for TDM-induced Mincle expression and production (117, 118).

Complement receptors CR1 (CD35), CR3 (CD11b/CD18), and CR4 (CD11c/CD18) are major phagocytic receptors expressed by monocytes, macrophages, neutrophils, and some lymphocytes, and their expression and activities change in a tissue- and differentiation-specific manner (Fig. 2). For example, CR4 expression increases during differentiation of monocytes into mac-

rophages and is the prominent CR on AMs (119, 120). CRs mediate phagocytosis of opsonized and nonopsonized *M. tuberculosis* by human macrophages (67, 68, 121, 122) and recognize surface polysaccharides, PIMs, and glycopeptidolipids of nonopsonized *M. tuberculosis* (123, 124).

Fc γ Rs play a role in the phagocytosis of *M. tuberculosis* following opsonization of bacteria with immune-specific antibody (67); this can lead to increased PL fusion (125).

TLRs

TLRs are a highly conserved family of transmembrane PRRs that are expressed by many cells, including AMs

and DCs (126–130) (Fig. 2). They are surface exposed (e.g., TLR2 and TLR4) and intracellular (e.g., TLR9) (127) and are classically thought of as proinflammatory through NF κ B activation (131–133) but can also act through the negative regulators TRIF, IRF, and IRAK-M (134, 135). Recognition of *M. tuberculosis* occurs via TLRs 2, 4, and 9. Mycobacterial lipids (phosphor-*myo*-inositol-capped LAM, PIM₂, and PIM₆) and 19-kDa lipoprotein are TLR2 agonists (136, 137). TLR4 recognizes heat shock protein 65 (136), and TLR9 recognizes *M. tuberculosis* CpG motifs (138). Studies in TLR knockout mice with *M. tuberculosis* have yielded contradictory results. Single and double knockout mice exhibit a range of phenotypes in response to *M. tuberculosis* infection including enhanced mortality and defective IL-12p40 and IFN- γ responses (139–142). Conversely, triple knockout TLR2/4/9 mice exhibited no loss of protective T cell responses, and growth of *M. tuberculosis* was similar in wild-type and knockout mice (143). Myeloid differentiation factor 88 (MyD88), an adaptor used by most TLRs, was reported to be indispensable for control of mycobacterial growth (143, 144), although MyD88's role may be tied to its importance in IL-1 β signaling (145).

SRs

There are at least eight classes of SRs, which cooperate with other receptors to mediate their function (146) (Fig. 2). AMs express at least four different SRs: the class A scavenger receptor-A isoforms I and II (SRA-I/II), macrophage receptor with collagenous structure (MARCO), and the class B receptor CD36. SRA-I/II bind to most polyanionic molecules (147, 148), MARCO removes unopsonized particles in the lung (149), and CD36 removes apoptotic cells and oxidized LDL (150). SRs mediate *M. tuberculosis* binding to macrophages (151). MARCO cooperates with TLR2 and CD14 to initiate cytokine release following recognition of *M. tuberculosis* TDM (152). CD36 contributes to foam cell generation during *M. tuberculosis* infection (153) and PPAR γ production during BCG infection (154). PPAR γ induces CD36 expression in human AMs (155). The specific role of different SRs during *M. tuberculosis* infection is unclear, likely due to a redundancy in scavenger receptor expression (156). Infection of SRA-I/II (157, 158) and MARCO (159) single knockout mice indicates that these SRs may play a role in limiting inflammation and resistance to pulmonary pathogens. CD36 knockout mice are more resistant to *M. tuberculosis* infection (160). Further work is needed to understand the role of SRs during *M. tuberculosis* infection.

Phagosome maturation

Typical phagosome maturation involves sequential fusion of the phagosome with early endosomes, late endosomes, and lysosomes, during which process the pH decreases to 4.5 to 5.0 through the actions of a vacuolar ATPase. The phagosome also acquires antimicrobial peptides and proteases, including cathepsins that are activated by the low pH in the phagosome. These factors all contribute to the bactericidal nature of the mature phagosome and mediate clearance of the ingested particle (161). However, some pathogens, including *M. tuberculosis*, modify the phagosome such that it becomes a niche for intracellular replication (Fig. 3). *M. tuberculosis* phagosomes do not fully acidify, reaching a pH of 6.2, and do not fuse with lysosomes (Rab5, but not Rab7, is acquired). Many *M. tuberculosis* components interfere with this maturation, including ESAT-6/CFP-10 (early secretory antigenic target 6/culture filtrate protein 10), SecA1/2, ManLAM, and TDM (102, 162–165). ManLAM inhibits PL fusion through the macrophage MR (87). Recent work showed that a mycobacterial lipoprotein, LprG, binds ManLAM and controls its distribution in the mycobacterial envelope. Mutants of *M. tuberculosis* lacking LprG have less ManLAM on their surface and are less able to inhibit PL fusion (166, 167).

It has been proposed that *M. tuberculosis* can escape the phagosome and reside in the cytosol. This is controversial, with debate as to whether *M. tuberculosis* replicates in the cytosol or is released in conjunction with macrophage cell death (168). Cytosolic localization has been proposed because experiments in the 1980s to 1990s provide electron microscopy images showing intracellular *M. tuberculosis* independent of phagosomal membranes (169–171), and components of *M. tuberculosis* are detected in the cytosol following infection in a region of difference-1 (RD-1) and ESAT-6-dependent manner (172–174). An explanation for the latter observation, besides complete phagosomal membrane dissolution, is that the RD-1-dependent ESX-1 secretion system perforates, but does not destroy, the phagosomal membrane, resulting in a “leaky,” or porous, phagosome (175, 176). This leaky phagosome would allow *M. tuberculosis* components access to the cytosol and explain how *M. tuberculosis* infection leads to activation of cytosolic immune sensors.

Autophagy

Macroautophagy is a major form of autophagy, hereafter referred to simply as autophagy, which involves the entrapment of cytosolic compounds into double-membrane vesicles that fuse with lysosomes to mediate




Figure 3 *M. tuberculosis* (*M.tb*) fate upon macrophage infection. Following phagocytosis, *M. tuberculosis* resides within a modified phagosome which may allow mycobacterial components to enter the cytosol in an ESX-1-dependent manner. The *M. tuberculosis* phagosome is also connected to the early endosomal network because membrane compartments can both fuse and bud from the phagosome, allowing exposure to important nutrients such as iron as well as removal of mycobacterial components. Endosomes containing mycobacterial components can fuse with multivesicular bodies (MVBs), leading to their incorporation into intraluminal vesicles, and upon MVB fusion with the plasma membrane, they can be released within exosomes (indicated as red circles in the figure). The *M. tuberculosis* phagosome has limited fusion with lysosomes, but with activation by IFN- γ or antibiotic treatment the *M. tuberculosis*-containing phagosome may undergo autophagosome formation and following lysosome fusion can limit *M. tuberculosis* growth, a process known as autophagy. There are also data suggesting that *M. tuberculosis* can escape into the cytosol, although this has been observed in only a limited number of studies.

degradation. This process is involved in cell maintenance and can also be used to limit infection (177–179). Starvation, rapamycin, TLRs, 2'-5' cyclic GMP-AMP, IL-1, and IFN- γ can all induce autophagy (180). Recent publications have indicated that the host AMP-activated protein kinase-PPAR γ , coactivator 1 α pathway (AMPK-PPARGC1A; PGC-1), and membrane occupation and recognition nexus repeat containing 2 (MORN2) are involved in autophagy induction and regulate *M. tuberculosis* infection (181, 182) (Fig. 3). *M. tuberculosis* has various components that regulate autophagy, including ESAT-6 (176, 183) and the enhanced intracellular survival (*eis*) gene (184). If autophagy is induced, *M. tuberculosis* colocalizes with the autophagy marker LC3, PL fusion occurs, and *M. tuberculosis* growth is limited (185, 186). Autophagy is important *in vivo*; autophagy-deficient mice show increased *M. tuberculosis* growth, lung pathology, and reduced survival compared to wild-type mice (176, 187). Two frontline TB drugs, isoniazid and pyrazinamide, induce autophagy in *M. tuberculosis*-infected macrophages and are more inhibitory toward *M. tuberculosis* growth if the autophagy machinery is intact (188). Manipulation of autophagy is being pursued as a treatment option for TB (189–192).

Intracellular receptors

Intracellular receptors include the transmembrane TLRs and cytosolic nucleotide-binding oligomerization domain-containing protein (NOD)-like receptors (NLRs), RIG-I-like receptors, AIM2-like receptors (ALRs), and other cytosolic DNA sensors (193–197). Some of these receptors have been shown to recognize *M. tuberculosis* ligands and play a role during *M. tuberculosis* infection.

NOD1 recognizes D-glutamyl-meso-diaminopimelic acid, while NOD2 recognizes muramyl dipeptide (MDP) and a glycolated form of MDP (GMDP) produced by *M. tuberculosis* (198–200). NOD2 regulates *M. tuberculosis* growth in human and murine macrophages (201–203), perhaps via release of antimicrobial peptides and autophagy, since MDP increases LL-37, IRGM, and LC3 expression and *M. tuberculosis* killing in AMs (204). *M. tuberculosis* infection also activates NLRP3, but NLRP3 function during infection is unclear since NLRP3-deficient mice show a similar susceptibility to *M. tuberculosis* infection as wild-type mice. On the other hand, mice lacking the adaptor protein PYCARD/ASC, which (like NLRP3) is involved in caspase-1 activation, are more susceptible to *M. tuberculosis* infection (205). AIM2 and the ALR IFI204 recognize DNA and may play a role during *M. tuberculosis* infection (175, 206); AIM2-deficient mice have a

higher bacterial burden and succumb to infection more quickly than wild-type mice (207).

PPAR γ

The PPARs are a family of nuclear receptor-associated transcription factors. They include PPAR α , PPAR β/δ , and PPAR γ (208, 209). PPAR γ is highly expressed by AMs, and its deletion leads to increased expression of IFN- γ , IL-12, macrophage inflammatory protein 1 alpha, and inducible nitric oxide synthase (210). PPAR γ expression is induced in macrophages through the MR and TLR2 by *M. tuberculosis* and BCG, but not by the avirulent *M. smegmatis* (23, 211). PPAR γ inhibition or knock-down leads to reduced *M. tuberculosis* intracellular replication and lipid body formation and enhanced TNF- α production (23, 153, 211). PPAR γ is actively being pursued as a drug target, and efforts are ongoing to increase our understanding regarding its activities (209).

microRNAs (miRNAs)

miRNAs are endogenous, noncoding small RNAs that are typically transcribed from intergenic or intragenic regions of the genome in the pri-miRNA form. Following processing into miRNAs, they bind target mRNAs and typically mediate translational repression or mRNA degradation (212–214). Recent attention has focused on the specific regulation and function of miRNAs in the lung, particularly regarding cancer and inflammatory responses (215, 216). miRNAs serve several potential functions during *M. tuberculosis* infection: regulating TLR signaling, NF κ B activation, cytokine release, autophagy, and apoptosis to alter *M. tuberculosis* infection and host survival (22, 217, 218). For example, miR-124 downregulates expression of MyD88, TRAF6, and TLR6 (219), and miR-let-7f targets a negative regulator of NF κ B, A20, to increase cytokine and nitrite production and reduce *M. tuberculosis* infection (217). miR-132 and miR-26a negatively regulate the transcriptional coactivator p300 and IFN- γ signaling (220). Expression of miRNAs can be altered in *M. tuberculosis*-infected patients or cells (220–226), sometimes in a virulence-dependent manner; e.g., *M. tuberculosis*, but not *M. smegmatis*, infection induces expression of miR-125b (227). miRNA activity can also be cell-type specific, because miR-19a-3p may regulate expression of 5-lipoxygenase in primary human T cells, but not B cells (228). Targeting of miRNAs is a promising host-directed therapy (229).

Macrophage release of exosomes

miRNAs are also transported between cells via exosomes. Exosomes are membrane-bound vesicles of endo-

cytic origin that are released from most nucleated cells and function in intercellular communication and immune cell activation and serve as a source of disease biomarkers (230). In the context of an *M. tuberculosis* infection, exosomes released from infected macrophages can carry mycobacterial components including LAM, 19-KDa lipoprotein, and over 40 bacterial proteins, many of which are known immuno-dominant antigens (231, 232) (Fig. 3). The exosomes released from infected compared to uninfected macrophages also differ in their RNA content, and this has functional consequences on the exosome-recipient cell (233). Moreover, exosomes released from infected macrophages elicit both innate and acquired immune responses *in vitro* and *in vivo* and when used as a vaccine can protect mice against an aerosolized infection (231, 234, 235). However, whether exosomes released from infected macrophages function in regulating the immune response in humans during an *M. tuberculosis* infection remains an open question.

Macrophage cell death

Cell death can be an important step in controlling infection, and as such, many pathogens manipulate host cell death pathways to enhance their survival (236). The two cell death pathways that have been most studied are apoptosis, which is commonly thought of as anti-inflammatory and is characterized by retention of cell membrane integrity, and necrosis, which is typically proinflammatory and characterized by loss of membrane integrity (237, 238). Pyroptosis has characteristics of necrosis and apoptosis; pyroptotic cells lose membrane integrity similar to necrotic cells, but cell death is caspase-dependent, similar to apoptosis (239). Virulent *M. tuberculosis* inhibits apoptosis and instead induces necrosis to exacerbate infection. Apoptosis prevents *M. tuberculosis* dissemination and enhances antigen presentation to DCs and T cell priming. Necrosis and necroptosis mediate *M. tuberculosis* exit and dissemination from the infected cell, propagating infection; *M. tuberculosis* may downregulate pyroptosis, but this is not clear (240–242). *M. tuberculosis* components involved in regulating cell death include SodA, NuoG, ESX-1, and ESX-5 (243).

Interaction with DCs

DCs are a unique subset of immune cells which under steady-state conditions function as sentinels of the immune system. Immature DCs phagocytose *M. tuberculosis* at the site of infection, mature, migrate to secondary lymphoid organs, and prime T cells. DCs are equipped with a repertoire of PRRs for PAMPs

and damage-associated molecular pattern molecules (DAMPs) (Fig. 4). Engagement of individual receptors can ultimately dictate downstream DC responses. TLRs 2, 4, and 9 and DC-SIGN recognize *M. tuberculosis* surface molecules, as discussed above. The interaction between DC-SIGN and ManLAM expressed on virulent mycobacteria is exploited by *M. tuberculosis* to its benefit, with *M. tuberculosis* using DC-SIGN as a portal into DCs; once engulfed, bacteria are targeted to late endosomes/lysosomes expressing lysosomal-associated membrane protein 1 (LAMP1) (100). DC-SIGN-mediated entry leads to IL-10 production and inhibition of DC maturation (100), which in turn causes inefficient T cell priming and a state of antigenic tolerance (244). Mycobacteria are able to persist in DCs (245, 246). Other mycobacterial products such as Hip1, a serine hydrolase, modulate DC responses and intracellular survival of the pathogen. Hip1 mutants of *M. tuberculosis* induce high levels of IL-12 and increased expression of MHC-II in a MyD88- and TLR2/9-dependent manner (247). *M. tuberculosis* is also able to retain coronin-1 on the vesicular membrane, which interferes with phagosome maturation and promotes survival of the pathogen (245). Lung DCs encompass three major subsets of cells: conventional DCs, plasmacytoid DCs, and monocyte-derived DCs, with each subset having specific and interrelating functions in the host (248). Data from mouse studies show that monocyte-derived DCs are rapid responders and are detected in the lung as early as 48 hours postinfection (249, 250). DCs undergo phenotypic changes following engulfment of mycobacteria which include upregulation of MHC-I/II, CD40, CD80, and CD86 (251); increased production of IL-12, TNF- α , IL-1, and IL-6 (252–254); and increased migration to lymph nodes for T cell antigen presentation (255).

In specialized microenvironments, migratory DCs are able to efficiently prime CD4 T cells (256) and activate CD8 T cells by the endosome-cytosol (257) or “detour” (258) antigen presentation pathway. DCs possess a pathway capable of transferring exogenous antigens from the endosome to the cytosol, leading to the presentation of antigens via the classical MHC-I pathway (173, 257). As part of the “detour pathway” uninfected DCs engulf apoptotic vesicles released from *M. tuberculosis*-infected macrophages and present antigens from these extracellular vesicles to CD8 T cells (258).

DCs (in addition to macrophages) are key initiators of the immune response and are thought of as Trojan horses providing a reservoir for *M. tuberculosis* to survive and escape immune surveillance (259, 260). Char-

- Mycobacterium orygis*, 460, 476, 479, 496, 498
- Mycobacterium phlei*, 6, 295
- Mycobacterium pinnipedii*, 460, 461, 476, 477, 479
- Mycobacterium prototuberculosis*, 458
- Mycobacterium smegmatis*, 10, 308–309, 535, 536, 609, 673, 675, 679, 703
replisome components, 584–586, 587
- Mycobacterium suricattae*, 496
- Mycobacterium szulgai*, 382
- Mycobacterium tuberculosis*, 3;
see also HIV-TB coinfection
ATP synthesis by F₁F₀ ATP synthase, 308–309
chemokines and cytokines in adaptive response to, 38
chemokines and cytokines in innate response to, 37
chemokines in, infection, 49–53
cytokines in, infection, 34–49
emerging strains inducing regulatory T cells in lungs, 150
Erdman strain, 166, 167, 168, 170, 171–172
fate upon macrophage infection, 9
H37Rv strain, 166, 167, 168, 170, 172
HIV-1 heterogeneity at site of disease, 247
HIV-1 replication at site of disease, 245–247
hypothesized states of response to infection, 214
immune system, 95
interactions with macrophages, 6–8, 10–11
interaction with granulocytes, 14–16
interaction with lung, 6–16
latent TB infection (LTBI), 217, 226, 227
macrophage receptors, 7
mouse response to infection, 146–150
mutagenesis in, 595
oxidative phosphorylation in, 295
pathology of, 117–121, 125–127, 672
physiology for nonreplicating persistence, 567–571
prevention of infection, 193–195
primary host response to infection, 122–123
protein phosphorylation in, 557, 559–560
pulmonary innate immune cells during infection, 4
replisome components, 584–586, 587
respiration overview in, 295
responses of innate immune cells to, 12
schematic of electron transfer components, 296
spectrum of infection, 379–380
targeting primary dehydrogenases in, 299–302
targeting proton motive force (PMF) in, 295–299
vaccination, 95–96
- Mycobacterium tuberculosis* complex (MTBC), *see also* Evolution of MTBC
biological differences among *M. tuberculosis* strains, 482–484
biological differences between animal and human MTBC lineages, 481–482
biological differences between *M. canettii* and, 482
biological impact of genetic diversity, 480
evidence for potential of biological variation, 480–481
geographical distribution of Beijing isolates, 483
global emergence of multidrug-resistant TB strains, 475–477
global genetic diversity, 477–484
global phylogenetic structure of MTBC strains, 476
global phylogeny of MTBC isolates, 465
inpatient diversity, 479–480
phylogenetic reconstruction of MTBC Beijing lineage population, 478
- Mycobacterium tuberculosis* infection, *see also* Protein phosphorylation
apoptosis, 563
cell wall remodeling, 569–570
defense against host-generated reactive oxygen and nitrogen species, 563–564
growth arrest, 567–569
Ser/Thr protein kinases (STPKs)
 coordinating physiology of, 567–571
 slowing central metabolism, 570–571
 STPK cell signaling network, 568
 subversion of innate immune response, 560–564
- Mycobacterium tuberculosis* in macrophage
bottleneck response, 637
chemical genetics of infection, 643–644
cholesterol, 645, 646
construction of reporter strains, 638–639, 640
drug sensitivity of, 641
environmental cues and responses, 638
fatty acids, 644–645
flow cytometry gating strategy, 642
flow sorting strategy, 641
guilt-by-association analysis, 637
life and death dynamics, 637
lipid acquisition from host cell, 647
lipid utilization by, 644
manipulating host cell for nutritional purposes, 647–648
minimal unit of infection, 635, 648
phagocytosis, 636
replication clock plasmid, 637
response of *M. tuberculosis* to intracellular environment, 636–638
role of isocitrate lyase (Icl) and methyl citrate cycle (MCC), 645–647
single-cell suspension, 639–642
- Mycobacterium tuberculosis*-macrophage biology
downstream proinflammatory signaling, 547–548
innate immune sensing, 547–548
modulation of cell death pathways, 547
phagosome maturation arrest, 546
principles of, 546–548
survival in the face of host antimycobacterial molecules, 546–547
- Mycobacterium tuberculosis sensu stricto*, 454, 476, 477
- Mycobacterium ulcerans*, 495
- Mycobacterium vaccae*, 197
- Mycolic acids
 chemical structures of, 520
 importance of, 523–524
 loss of acid-fastness, 519, 529
- Myxococcus xanthus*, 673
- N**
- NADH:menaquinone oxidoreductases, 299–300
- National Institute for Health and Care Excellence (UK), 379
- National Institute of Allergy and Infectious Diseases, 117
- National Primate Research Centers (NPRCs), 164, 165, 166, 170, 171, 172
- National TB Costing Model, 395, 398
- Natural killer (NK) cells
 HIV-TB coinfection, 244–245
 memory, 107
 M. tuberculosis infection, 12–14
- Natural resistance-associated macrophage protein (*Nramp*), 146
- Neanderthals, 467
- Necrosis-associated extracellular clusters (NECs), 151, 153
- Necrotizing lesions
 biofilms as perspective of extracellular *M. tuberculosis* in, 535–536
 characteristic of active pulmonary TB, 533–534
 extracellular *M. tuberculosis* in, 534–535
- Neelsen, F., 520
- Neisseria meningitidis*, 197
- Neutrophils
 HIV-TB coinfection, 243–244
 lung, 5
 M. tuberculosis infection, 12, 39, 216, 548
 response to *M. tuberculosis*, 125
- Niclosamide, 343–344, 346
- Nicotinamide, 706
- Nigericin, 297, 298
- Nile red stain, 526–527
- Nitro-containing compounds, dual- and nonreplicating active, 343, 344
- 3-Nitropropionate, 300, 301
- Nocardia farcinica*, 13
- Nongrowing but metabolically active bacteria (NGMA), 676
 identification of, 678, 681, 683
- Non-human primate models, *see also* Animal models
 animal model, 132–133
 comparison of rhesus and cynomolgus macaque models, 165–167
 cynomolgus macaques, 166–167, 169
 future research strategies, 172
 historical use of macaque models, 163–165
 in vitro, 544–545
 macaque models for study of TB pathogenesis, 171
 macaque models for TB drug evaluation, 170–171
 macaque models for TB vaccine evaluation, 167, 170
 M. tuberculosis/simian immunodeficiency virus coinfection, macaque models, 171–172

- Non-human primate models (*Continued*)
 preclinical efficacy models, 283–284
 rhesus macaques, 165, 166, 168
 Treg cells in, 80, 86–87
 validation of macaques in TB
 research, 163
- Nonreplicating (NR) models, selecting and
 designing, 323, 324
- Nonreplicating persistence (NRP)
M. tuberculosis physiology for, 567–571
 sensing when to exit NRP, 571–572
- Nonreplication, diversity in, 319–321
- Nontuberculous mycobacteria (NTM), 495
- Nucleic acid amplification testing (NAAT),
 390, 391, 392; *see also* GeneXpert
 MTB/RIF technology
- Nutrient use of pathogens, *see also*
 Auxotrophies
 amino acid auxotrophies, 701–706
 cofactor auxotrophies, 706–708
 future perspectives, 708–710
 lessons from auxotrophic strains, 701–708
 lessons from metabolomics, 700–701
M. tuberculosis in host tissue, 701
M. tuberculosis in macrophages, 700–701
- O**
- Ofloxacin, drug resistance, 505
- Oxford University, 200
- Oxidative phosphorylation
 growth reactivation, 301–302
M. tuberculosis, 295
- P**
- Pääbo, Svante, 467
- Paleomicrobiology, 467
- PAMP (pathogen-associated molecular
 pattern), *M. tuberculosis*-derived, 246
- Pantothenate (vitamin B₅), 706
- Paradigm, 121
- Parkinson diseases, 630
- Pathogenesis
 application of animal models, 134–135
 macaque models for studying TB, 171
 persistence, 672
- Pathogens, *see* Nutrient use of pathogens
- Pathology of tuberculosis, 117–121,
 125–127
 alveolar pneumonia, 126
 cavity formation, 119, 120
 disease progression in animal models, 122
 granuloma within the lung, 118
 hypersensitivity of pathogenesis of post-
 primary TB, 123–125
 intrapulmonary spread of mixed
 inflammatory cells, 121
 lipid pneumonia, 121, 125
 obstructive lobular pneumonia, 121, 123
 post-primary lung reinfection, 124–125
 primary host response to *M. tuberculosis*
 infection, 122–123
- Pattern recognition, 145
- Penicillin, 317–318
- Peripheral blood mononuclear cells
 (PBMCs), 4
- Peroxisome proliferator-associated receptor
 gamma (PPAR γ), 4, 10
- Persistence
 definition, 654
 drug-induced, 662
 gene deletion studies, 659–661
 host-induced, 657–662
 measurements, 656–662
 messages, 662–663
 methods, 656
 models, 654–656
 pathogenicity of *M. tuberculosis*, 653, 672
 physiology of *M. tuberculosis*, 653
 predicted genes for *in vivo* survival of
M. tuberculosis, 661
 terms, 653–654
- Persisters, 317
 class I, 321–322
 class II, 322–325, 329–346
 diversity in nonreplicating cells, 319–321
 killing class II persisters, 329, 331–341
- Phagocytosis, 636
- Phagosome maturation, 8, 9
- Phenotype, 671
- Phenotypic definitions, 429
- Phenotypically tolerant *M. tuberculosis*,
 317–319
 class I persisters, 321–322
 class II persisters, 322–325, 329–346
 compound transformation during
 screening and secondary assays,
 325, 329
 conditions for replication rates of, 326
 designing high-throughput screens to
 target, 322–325
 diversity in nonreplication, 319–321
 evaluating bactericidal action against
 nonreplicating mycobacteria, 329
 fluoroquinolones, 339
 future studies, 347–348
 high-throughput screening (HTS),
 341–343
 key observations, 319
 key recommendations, 348
 killing class II persisters, 329, 331–341
 membrane depolarizers, 343–346
 modeling hypoxia and metronidazole
 activity relationship, 318
 molecules targeting nonreplicating
 mycobacteria, 346, 347
 nitro-containing compounds, 343
 postscreening assays, 327, 328
 proof-of-concept molecules, 331–332
 proteolysis/proeostasis pathway, 339–341
 quinolines and derivatives, 338–339
 screening assays, 325, 329, 330
 selecting and designing nonreplicating
 models, 324
 strategies for evaluating viability of
 nonreplicating, 323
- Phenotypic drug resistance, 317
- Phenotypic heterogeneity, 671–672
 asymmetric cell division and cell aging,
 676–679
 causes and consequences of, 673
 flow cytometry and omics, 682–684
 fluorescence recovery after photobleaching
 (FRAP), 678, 684
 growth phase, 674–675
 growth rate, 675–676
 host microenvironment, 679–682
 host-mimicking platforms, 685–686
in vivo investigation, 685–686
 stochastic processes, 672–674
 stress conditions enhancing, 677
 time-lapse microscopy and microfluidics,
 684–685
 tools and methodology, 682–686
- Phenotypic tolerance, 317
- Phosphorylation, *see* Protein
 phosphorylation
- Pneumonia, tuberculosis as obstructive
 lobular, 121, 123
- Positron emission tomography/computed
 tomography (PET/CT), 171, 213,
 283, 680–681, 686
- Post-primary tuberculosis, 124–125
- Preclinical efficacy testing, 271, 274
 animal infection models of active TB,
 277–284
 drug candidates, 272–273
 dynamic drug concentration models,
 275–277
 goals of, 274–275
 guinea pigs, 282
 hollow fiber system model of TB, 275–277
in vitro models, 275–277
 mice, 278–281
 modeling chemotherapy of latent TB
 infection (LTBI), 284–286
 non-human primates, 283–284
 rabbits, 283
 rats, 281–282
 static drug concentration models, 275
- Preclinical studies, role in experimental
 medicine studies, 205–206
- Pretomanid
 drug candidate, 273
 guinea pigs, 282
 mice, 279
- Prime, vaccine development, 197
- Prime-boost, vaccine development, 197
- Programmed cell death protein-1 (PD-1),
 101–102
- Proline auxotroph, 703
- Proof-of-concept molecules
 dual actives with *in vivo* efficacy, 331–332
 nonreplicating actives with *in vivo*
 efficacy, 332
 nonreplicating activity, 333
 selective nonreplicating activity, 331
- Protein-adjuvant TB vaccines, 198–200
- Protein kinase activity, 557
- Protein phosphorylation, *see also*
Mycobacterium tuberculosis infection
 apoptosis, 563
 biochemically verified substrates of
M. tuberculosis serine/threonine
 protein kinases (STPKs), 558–559
 effect on *M. tuberculosis* STPKs, 566
 growth and persistence phenotypes of
M. tuberculosis STPKs, 562
 hierarchy of *M. tuberculosis* STPK
 activation, 561
 inhibition of phagosome-lysosome fusion,
 561, 563
M. tuberculosis, 557, 559–560
 STPKs coordinating *M. tuberculosis*
 physiology, 567–571
 STPKs regulating *M. tuberculosis*
 morphology, 564–565, 567
- Proteomics, 679, 683–684

- Proton motive force (PMF), 297
 mechanisms, 297
 targeting, in *M. tuberculosis*, 295–299
 traditional inhibitors of PMF
 generation, 298
- Pseudomonas*, 673
- Pseudomonas aeruginosa*, 13, 321, 467, 536, 591, 594
- Pseudomonas putida*, 591
- Pseudonocardia dioxanivorans*, 498
- PubChem, 329
- Purine auxotroph, 708
- Pyrazinamide, 528, 681
 drug resistance, 502, 504
 proof-of-concept molecule, 333
 tolerance of infected cells, 640
- Pyridoxamine (vitamin B₆), 706–707
- Pyrizinamide, 86
- ## Q
- QuantiFERON-TB (QFT) Gold In-Tube
 assay, 382, 384, 385
- QuantiFERON-TB Gold-Plus (QFT-Plus), 383
- QuantiFERON technology, 382–384, 385
- Quinoliny pyrimidines (QPs), TB drug, 300, 305
- ## R
- Rabbits
 animal model, 133
 granulomas in lungs, 126
 preclinical efficacy models, 283
 response to infection, 123, 124
 TB disease progression, 122
- Rapid speciation strip tests, 364
- Rats
 animal model, 133–134
 preclinical efficacy models, 281–282
- Recombinant mycobacterial vaccines, 202–203
- Regulation of TB immunity, *see also* Animal models; Human tuberculosis (TB)
 antigen-presenting cells (APCs), 74, 75
 human regulatory T (Treg) cells and anti-TB treatment, 78–79
 human Treg cells and clinical *M. tuberculosis* strains, 78
in vitro expansion of mycobacteria-specific Treg cells, 76–77
 mechanisms of Treg suppression, 74
 naturally occurring and induced Treg cells, 73–74
 Treg activity balance, 77
 Treg cell, 73–74
 Treg cell responses in experimental animal models of TB, 80–87
 Treg cell responses in human TB, 74–80
 Treg-mediated manipulation of immune cell activation, 75–79
 Treg responses at *M. tuberculosis* infection site, 79–80
 Treg suppression of APCs, 75
- Regulatory cytokines
 IL-4, IL-5, and IL-13, 47–48
 interleukin IL-10, 48–49
 transforming growth factor β (TGF β), 48
- Replication rate, 592; *see also* DNA replication
 mycobacterial, 592–594
- Research Institute of Influenza
 (St. Petersburg, Russia), 202
- Respiration, *M. tuberculosis*, 295
- Restriction fragment length polymorphism (RFLP) method, 454–455, 583
- Retroviridae family, 239
- Rhesus macaques, 163; *see also* Macaque models
 comparing TB in humans to, 164
 “Golden Age” of TB research using, 165, 166
Macaca mulatta, 163, 173
 TB studies, 166, 167, 168
 21st century TB research, 166
- Rhizobium leguminosarum*, 613
- Rifampin, 86, 527–528
 animal models, 279–280
 drug candidate, 272, 274, 278, 331
 drug resistance, 503, 504, 674
 guinea pigs, 282
 latent TB infection, 285–286
 line probe assays for detecting resistance, 367–368
 non-human primates, 283
 proof-of-concept molecule, 333
 tolerance of infected cells, 639–641
 Xpert MTB/RIF for resistance to, 368
- Rifapentine
 drug candidate, 272
 guinea pigs, 282
 latent TB infection (LTBI), 285–286
- ## S
- Salmonella*, 146, 321, 674, 676
- Salmonella enterica* serovar Typhi, 462
- Salmonella typhimurium*, 557
- Sanofi Pasteur, 199
- Scavenger receptors (SRs), 8
- SciFinder, 329
- Screening
 acidic pH, 341, 342
 biofilms, 341, 343
 hypoxia, 341, 342
 multiple physiological stresses, 341, 342
- Screening assays
 compound transformation during, 330
 designing high-throughput screens for phenotypically tolerant mycobacteria, 322–323, 325
 post-, 327, 328
 potential compound transformation during, 325, 329
- Secretion (SecA1) pathway
 cell wall synthesis and remodeling factors, 609
 conserved, 607–608
 conserved SecA1 exportome, 608–611
 entering dormancy, 610
 exported virulence factors, 610
 lipoproteins, 609–610
 models of SecA1 export, 608
 reactivation/resuscitation from dormancy, 611
- Secretion (SecA2) pathway
 dormancy, 619
 features of SecA2-dependent substrates, 613
 identification, 611–612
- immunomodulation and, 618–619
 inhibition of apoptosis, 618
 KatB (catalase-peroxidase), 616
 Mce transporters, 614–615
 mechanism, 612–613
 models of SecA2 export, 608
 multiple components of Mce transporters, 615
 phagosome maturation arrest, 617
 PknG (eukaryotic-like serine-threonine kinase), 616
 protein export pathway, 611–613
 reactive radicals and, 619
 SBPs (solute binding proteins), 613–614
 secA2 mutant as vaccine candidate, 619–620
 SecA2 and DosR regulon, 616–617
 SecA2 exportome, 613–616
 SodA (Fe-superoxide dismutase), 615–616
 virulence and, 617–619
- Secretion system, *see also* ESX-1 (ESAT-6 secretion system-1)
 ESAT-6 (ESX-1), 627, 631–632
- Shuman, Stewart, 591
- Simian immunodeficiency virus (SIV), *M. tuberculosis* and, coinfection
 macaque models, 171–172
- Smear microscopy, diagnostics for active TB, 363–364
- Solute carrier, 146
- South Africa
 challenges and opportunities of implementation, 394, 396
 GeneXpert implementation, 397
 GeneXpert placement, 394
 national implementation of Xpert NTB/RIF assay, 393–394
 tuberculosis in, 391, 393
- South African Tuberculosis Vaccine Initiative (SATVI), 104, 105
- Spectroscopy, 683–684, 701
- Spoligotyping, 455, 457, 461
- Staphylococcus aureus*, 609, 611
- Statens Serum Institut, Denmark, 198
- Stead, W. W., 654
- Stem cell-like memory T cells, 102
- Streptococcus gordonii*, 611
- Streptococcus parasanguinis*, 611
- Streptococcus pneumoniae*, 197, 536
- Streptomyces coelicolor*, 591
- Streptomycin, drug resistance, 502, 505
- Succinate:quinone oxidoreductase, 300–301
- Swedish Institute of Infectious Disease Control, 167
- Systems biology, tuberculosis, 429
- ## T
- TB-associated immune reconstitution inflammatory syndrome (TB-IRIS), 76
- T cells, *see also* Memory T cells
 cytotoxic, in TB-immune reconstitution inflammatory syndrome (TB-IRIS), 255–256
M. tuberculosis infection, 217–219, 548–549
 responses to tuberculosis (TB), 225
- Technical Expert Group, 365
- Thioalkalivibrio*, 458
- Thiorhodovibrio*, 458

- Thioridazine, 297, 299
 Threonine auxotroph, 704
 Time-lapse microscopy, 684–685
 Tissue remodeling, tuberculosis (TB), 225
 Toll-like receptor 9 (TLR9), 4
 Toll-like receptors (TLRs), 7–8, 39, 145
 Trained immunity, 13, 17, 107
 Transcriptional profiling, *M. tuberculosis* in macrophages, 636–638
 Transcriptome studies, 674, 683–684
 Transcriptomic profiling, biomarkers, 226–227
 Transforming growth factor β (TGF β), 48
 Transgenic mice, 145
 TraSH screening method, 704
 Treatment outcomes, impact of GeneXpert MTB/RIF, 401, 402–404
 Trifluoperazine, 299, 300
 Trudeau, E. L., 131
 Tryptophan auxotroph, 704–705
 Tuberculin skin testing (TST), 213, 214, 215, 220, 221, 225
 administering and reading TST, 381
 latent TB infection, 380
 purified protein derivative (PPD)-based TST, 381
 Tuberculosis (TB), *see also* Animal models; HIV-TB coinfection; Human tuberculosis (TB); Vaccine candidates
 adjunctive therapeutic vaccination, 196–197
 anti-TB vaccine design, 39
 biomarkers in human, 226–227
 diabetes mellitus, 222–223
 diversity, 680
 global epidemic, 389–390
 HIV-1 heterogeneity at site of disease, 247
 HIV-1 replication at site of disease, 245–247
 HIV and, 172, 222
 lung, 3–6
 malnutrition, 223–224
 necrotizing lesions in active pulmonary, 533–534
 positive and negative roles of chemokines in, 36
 positive and negative roles of cytokines in, 35
 post-primary, 119–121, 123–127
 preventing recurrent TB, 196–197
 prevention of disease, 195–196
 progression from infection to disease, 222–226
 proposed framework for spectrum of infection, 380
 protective memory against, 96–97
 risk factors for, 222
 systems biology of, 429
 targeting replisome for new drug development, 595–596
 Treg cell responses in human, 74–80
 vaccine, 40, 43, 45, 46, 49
 vaccine development strategies, 197–198
 vitamin D deficiency, 223
 Tuberculosis (TB) vaccination
 animal models, 80
 guinea pig model, 86
 mouse models, 83–84
 Tumor necrosis factor alpha (TNF α), 34–37
 roles in TB, 35
 Type I interferons (IFN- γ), tuberculosis, 224
- U**
 University of Pittsburgh, 166–167, 171
 University of Zaragoza and Biofabri, 202
 Urine lipoarabinomannan rapid test, 366
 U.S. Department of Agriculture, 139
 U.S. Food and Drug Administration (FDA), 382
- V**
 Vaccae, vaccine candidate, 197, 198, 202
 Vaccination
 adjunctive therapeutic vaccination, 196–197
 BCG and disease protection, 194
 clinical trials of TB candidates, 197–203
 M. tuberculosis, 95–96
 prevention of *M. tuberculosis* infection, 193–195
 prevention of recurrent TB disease, 196–197
 prevention of TB disease, 195–196
 Vaccine candidates, 198
 Ad5Ag85A, 201
 Crucell Ad35, 201
 DAR-901, 202
 development strategies, 197–198
 experimental medicine role in development, 203–206
 global clinical pipeline of, 198
 H1:IC31 and H1:CAF01, 198
 H4:IC31, 199
 H56:IC31, 198–199
 ID93+GLA-SE, 199
 inactivated whole-cell and fragmented TB vaccines, 202
 M72/AS01E, 199–200
 MTBVAC, 202–203
 MVA85A, 200–201
 Protein-adjutant TB vaccines, 198–200
 recombinant mycobacterial vaccines, 202–203
 RUTI, 202
secA2 mutant as, 619–620
 TB/Flu-04L, 202
 Vaccae, 202
 VAP 1002, 203
 viral-vectored vaccines, 200–202
 VPM 1002, 203
 Vaccines, *see also* Vaccine candidates
 Ad85A (human adenovirus 5 expressing Ag85A), 181–182
 animal models and testing protocols, 136, 137
 animal models for assessment of, 135
 antibody-inducing, 220
 BCG protection, 40, 43, 45, 46, 49, 220
 BCG vaccination in animals, 100
 BCG vaccination in guinea pigs, 86
 BCG vaccination in humans, 76, 100
 BCG vaccination in mice, 83–84
 biomarkers correlating disease severity, 184
 biomarkers predicting efficacy, 182
 guinea pig model, 153–154
 macaque models of evaluating TB vaccine, 167, 170
 mechanism of protection, 136
 memory immunity by novel TB, 107–108
Mycobacterium bovis bacillus Calmette-Guérin (BCG), 95, 117, 179–180
 new-generation TB, 180–182
 novel TB candidate MVA85A, 77–78, 96, 104, 108, 200–201
 predictivity of animal models, 137–138
 proof of concept for, 194, 196, 203–206
 role of experimental medicine in vaccine development, 203–206
 schedules of BCG and virally vectored, 183–184
 types of new, tested in cattle, 181
 Vakzine Projekt Management GmbH, 203
 Valine auxotroph, 704
 Valinomycin, 297, 298
 Vertex Pharmaceuticals, 643
Vibrio cholerae, 465
 Viral-vectored vaccines, 200–202
 Vitamin B₅ (pantothenate), 706
 Vitamin B₆ (pyridoxamine), 706–707
 Vitamin B₇ (biotin), 707
 Vitamin B₉ (folate), 707
 Vitamin B₁₂ (cobalamin), 707–708
 Vitamin D deficiency, 223
- W**
 Wallgren, Arvid, 215
 Wayne model, hypoxia, 318, 323, 325
 Whole-genome sequencing (WGS)
 emergence of, 495
 M. tuberculosis L2 Beijing sublineage, 500
 resistant strains, 502, 506–507
 World Health Organization (WHO), 193, 226, 239
 global TB epidemic, 389–390
 line probe assay recommendations, 368–369
 TB disease control, 379, 533
 TB screening, 363, 364
- X**
 XLAAD (X-linked autoimmunity allergic dysregulation syndrome), 73
 Xpert MTB/RIF, *see also* GeneXpert MTB/RIF technology
 background of, 391
 diagnostics for TB, 365, 368
 maximizing impact of new diagnostics, 371, 373–374
 timeline of availability, 374
- Y**
Yersinia pseudotuberculosis, 674
- Z**
 Zebrafish
 animal models, 133, 685, 686
 granuloma formation, 135
 in vitro model, 550
 M. marinum, 36, 133, 699
 Ziehl, F., 520
 ZN (Ziehl-Neelsen) stain, 519; *see also* AF (acid-fast) mycobacteria
 clinical diagnosis of TB, 522–523
 history of acid-fast (AF) staining, 520–522
 M. tuberculosis, 521, 528